Shows
PeerPOV: The Pulse on MedicineHER2+ Horizons: Debates and Decisions in Metastatic Breast Cancer: Episode 1First-Line Therapy—Has the Standard of Care Shifted for Good?In this episode, Dr. Sara Tolaney, of Dana-Farber Cancer Institute, discusses how DESTINY-Breast09 is redefining first-line treatment in HER2-positive metastatic breast cancer. She explores whether T-DXd plus pertuzumab should replace the long-standing THP regimen, the future role of induction-maintenance strategies, and open questions on optimal therapy duration. Let us know what you thought of this week’s episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com!2025-07-1416 min
Oncology News Central Peer-SpectivesGame-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer CareFrom a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tolaney, MD, MPH, chief of the Division of Breast Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Tolaney broke down some of the top data at ASCO 2025 with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles, California, and Steven Spielberg Family Chair in Hematology-Oncology. She singled out findings from the ASCENT-04 trial, the plenary session on SERENA-6, and the DESTINY-Breast09 trial. “I t...2025-07-1410 minOncology News Central Peer-SpectivesGame-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer CareFrom a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tolaney, MD, MPH, chief of the Division of Breast Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Tolaney broke down some of the top data at ASCO 2025 with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles, California, and Steven Spielberg Family Chair in Hematology-Oncology. She singled out findings from the ASCENT-04 trial, the plenary session on SERENA-6, and the DESTINY-Breast09 trial. “I t...2025-07-1410 min
ASCO Daily NewsBreast Cancer Research Poised to Change Practice From ASCO25Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a...2025-06-2331 min
Research To Practice | Oncology VideosBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesFeaturing perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics: Introduction: Adjuvant CDK4/6 Inhibition (0:00) HER2-Positive Disease (11:13) PARP Inhibition (27:34) Antibody-Drug Conjugates (34:12) Up-Front Treatment of HR-Positive Metastatic Disease (46:28) CME information and select publications2025-06-041h 01
Oncology Today with Dr Neil LoveBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesDr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. CME information and select publications here. 2025-06-041h 01
Breast Cancer UpdateBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesDr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. CME information and select publications here. 2025-06-041h 01
PeerView Clinical Pharmacology CME/CNE/CPE VideoSara M. Tolaney, MD, MPH - Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology PracticeThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBX865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 18, 2026.Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology Practice In support of improving patient care, this...2025-03-121h 02
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology PracticeThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBX865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 18, 2026.Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology Practice In support of improving patient care, this...2025-03-121h 02
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology PracticeThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBX865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 18, 2026.Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology Practice In support of improving patient care, this...2025-03-121h 02
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology PracticeThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBX865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until March 18, 2026.Elevating Excellence in HR+, HER2- EBC and MBC Care: Success Strategies for Community Oncology Practice In support of improving patient care, this...2025-03-121h 02
Patient from HellEpisode 82: Rewriting the Story of Triple-Negative Breast Cancer with Dr. Sara TolaneyIn this enlightening episode of the Patient From Hell, host Samira Daswani interviews Dr. Sara Tolaney, a leading oncologist specializing in breast cancer. They delve into the evolving landscape of triple-negative breast cancer (TNBC), exploring advancements in treatment, from targeted therapies to immunotherapy, and the challenges faced by patients in both early-stage and metastatic settings. With her characteristic warmth and expertise, Dr. Tolaney provides actionable insights for patients and caregivers, offering hope and understanding in navigating this complex diagnosis.
Key Highlights:
1. A New Paradigm in Early-Stage TNBC Treatment: Dr. Tolaney explains how neoadjuvant chemotherapy combined with immunotherapy has revolutionized...2025-01-2348 min
Oncology Brothers: Practice-Changing Cancer DiscussionsSABCS 2024 Highlights - DESTINY-Breast06, DESTINY-Breast12, PATINA with Dr. Sara TolaneyJoin us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies:
1. DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.
2. DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with bra...2025-01-1723 min
Oncology Brothers: Practice-Changing Cancer DiscussionsSABCS 2024 Highlights - DESTINY-Breast06, DESTINY-Breast12, PATINA with Dr. Sara TolaneyJoin us for another insightful episode of the Oncology Brothers podcast as we dive into the latest breakthroughs in breast cancer research from the San Antonio Breast Cancer Symposium 2024. In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Sara Tolaney from Dana-Farber Cancer Institute to discuss three pivotal studies:
1. DESTINY-Breast06 - An update on the efficacy of T-DXd in HER2 low and ultra-low breast cancer patients, highlighting its potential to change treatment paradigms for endocrine refractory disease.
2. DESTINY-Breast12 - Exploring the robust intracranial activity of T-DXd in patients with brain metastases and its impa...2025-01-1723 min
Research To Practice | Oncology VideosMetastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast CancerFeaturing perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications2025-01-102h 01Breast Cancer UpdateMetastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.2025-01-102h 01
Oncology Today with Dr Neil LoveMetastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.2025-01-102h 01
Research To Practice | Oncology VideosBreast Cancer | Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast CancerFeaturing perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics: Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00) Selection and Sequencing of Antibody-Drug Conjugates (5:09) Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39) Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04) Discussing Palliative and End-of-Life Care (32:40) PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53) The “Art of Oncology” — Building Trust with Patients and Family Members (45:05) Case: A woman in...2024-12-0559 minBreast Cancer UpdateExploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast CancerDr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer.2024-12-0559 min
Oncology Today with Dr Neil LoveExploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood and Dr Sara M Tolaney from Dana-Farber Cancer Center in Boston discuss recent updates on available and novel treatment strategies for metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here.
2024-12-0459 min
CME/CEChairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Host: Sara M. Tolaney, MD, MPH
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. FDA Approval January 2025:On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients wi...2024-09-3000 minCME/CEChairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Host: Sara M. Tolaney, MD, MPH
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. FDA Approval January 2025:On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients wi...2024-09-3000 minCMEChairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Host: Sara M. Tolaney, MD, MPH
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care. FDA Approval January 2025:On January 27, 2025, trastuzumab deruxtecan (T-DXd) was approved by the FDA for patients wi...2024-09-3000 min
Research To Practice | Oncology VideosHR-Positive and Triple-Negative Metastatic Breast Cancer | Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerFeaturing perspectives from Prof Peter Schmid and Dr Sara M Tolaney, including the following topics: Introduction: Pharmacology and Sequencing of Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) (0:00) Expanding Role of TROP2-Directed ADCs in mBC Management — Dr Tolaney (21:42) Other Targets for ADC Therapy in mBC — Prof Schmid (44:59) CME information and select publications2024-09-071h 02
Research To Practice | Oncology VideosHR-Positive and Triple-Negative Metastatic Breast Cancer | Sara M Tolaney, MD, MPHInside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer | Faculty Presentation 1: Expanding Role of TROP2-Directed Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer (mBC) Management — Sara M Tolaney, MD, MPH CME information and select publications2024-09-0728 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i...2024-09-071h 05PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i...2024-09-071h 05PeerView Oncology & Hematology CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i...2024-09-071h 05PeerView Clinical Pharmacology CME/CNE/CPE VideoSara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i...2024-09-071h 05
PeerView Internal Medicine CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i...2024-09-071h 05
PeerView Internal Medicine CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i...2024-09-071h 05Breast Cancer UpdateInside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast CancerProf Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.2024-09-061h 02
Oncology Today with Dr Neil LoveInside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.
CME information and select publications here
2024-09-061h 02
i3 Health PodcastAdditional Advances in Triple-Negative Breast Cancer Research and Trials: Sara M. Tolaney, MD, MPHLast year, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, served as co-chair of i3 Health’s webinar and online activity, Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC). With numerous advances in TNBC research occurring since then, Dr. Tolaney sat down with Oncology Data Advisor to share additional updates from clinical trials and a preview into the future of treatment with emerging therapies for TNBC.
To complete the CME/NCPD activity, follow this link: https://bit.ly/3KhoDVG2024-05-2407 min
Oncology Data AdvisorAdditional Advances in Triple-Negative Breast Cancer Research and Trials: Sara M. Tolaney, MD, MPHLast year, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, served as co-chair of i3 Health’s webinar and online activity, Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC). With numerous advances in TNBC research occurring since then, Dr. Tolaney sat down with Oncology Data Advisor to share additional updates from clinical trials and a preview into the future of treatment with emerging therapies for TNBC.2024-05-1707 min
Research To Practice | Oncology VideosMetastatic Triple-Negative Breast Cancer | Virtual Case Library: Metastatic Triple-Negative Breast CancerFeaturing perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics: Introduction: Overview of metastatic triple-negative breast cancer (mTNBC) Current and emerging strategies for patients with mTNBC (0:00) First-line treatment of mTNBC — Chemotherapy with or without immunotherapy Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10) Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41) Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15...2024-05-092h 12Breast Cancer UpdateVirtual Case Library: Metastatic Triple-Negative Breast CancerDrs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer.2024-05-092h 13
Oncology Today with Dr Neil LoveVirtual Case Library: Metastatic Triple-Negative Breast Cancer
Drs Rita Nanda, Sara M Tolaney, Julia Foldi, Laura Huppert and Saba Shaikh discuss available and emerging research, patient cases from participating junior clinical investigators and senior clinical investigator perspectives on relevant research data informing clinical decision-making for patients with metastatic triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here.
2024-05-082h 13
CCO Oncology PodcastReal-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast CancerIn this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:Challenges with the pathologic testing for HER2-low expressionOptimal treatment of patients with HER2-low advanced breast cancerRole of TROP-2–targeted therapiesManagement of ADC-associated adverse events to optimize treatment outcomesADCs on the horizon for patients with advanced breast cancerPresenters:Sara M. Tolaney, MD, MPHChief, Division of Breast OncologyDana-Farber Cancer InstituteAssoci...2024-03-1836 minASCO Daily NewsADCs in Breast Cancer: Sequencing, Resistance, and Managing ToxicityDrs. Hope Rugo and Sara Tolaney discuss the promise of antibody-drug conjugates (ADCs) in the treatment of breast cancer, highlighting key trials that shed light on matching the right ADC to the right patient in the right setting. They also explore how combinations and sequencing of ADCs can augment their efficacy, the mechanisms of resistance, and the future potential of biomarkers to predict patient response. TRANSCRIPT Dr. Hope Rugo: Hello, I'm Dr. Hope Rugo, your guest host of the ASCO Daily News Podcast today. I'm a professor of medicine and director of breast oncology and...2024-02-1530 minPeerView Clinical Pharmacology CME/CNE/CPE VideoJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...2024-02-1356 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...2024-02-1356 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...2024-02-1356 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastJoyce O’Shaughnessy, MD - Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBCThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for...2024-02-1356 min
VJOncology PodcastBreast Cancer Sessions: Highlights from SABCS 2023 with Sara Tolaney, Sarah Sammons & Paolo TarantinoThe San Antonio Breast Cancer Symposium (SABCS) 2023 took place on the 5-9th of December 2023 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.
In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2023 in an exclusive roundtable discussion. Topics covered include updates on the management of HR+/HER2- breast cancer such as the role...2024-01-1228 min
VJOncology PodcastBreast Cancer Sessions: Highlights from SABCS 2023 with Sara Tolaney, Sarah Sammons & Paolo TarantinoThe San Antonio Breast Cancer Symposium (SABCS) 2023 took place on the 5-9th of December 2023 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.
In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2023 in an exclusive roundtable discussion. Topics covered include updates on the management of HR+/HER2- breast cancer such as the role...2024-01-1228 min
Research To Practice | Oncology VideosBreast Cancer | Implications of Recent Data Sets for the Current and Future Management of Breast CancerFeaturing perspectives from Dr Aditya Bardia and Dr Sara M Tolaney, including the following topics: Introduction: Pan-tumor Approval of Novel Agents (0:00) Treatment of ER-Positive Localized Breast Cancer (7:49) Immunotherapy in Localized Breast Cancer (18:42) Antibody-Drug Conjugates in Metastatic Disease (Trastuzumab Deruxtecan, Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan) (37:21) CME information and select publications2023-11-301h 03Breast Cancer UpdateImplications of Recent Data Sets for the Current and Future Management of Breast CancerDr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress.2023-11-301h 03
Oncology Today with Dr Neil LoveImplications of Recent Data Sets for the Current and Future Management of Breast Cancer
Dr Aditya Bardia from Massachusetts General Hospital and Dr Sara M Tolaney from the Dana-Farber Cancer Institute, both in Boston, Massachusetts, discuss key presentations on the management of breast cancer from the 2023 ESMO Congress, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here.
2023-11-291h 03VJOncology PodcastLatest advances in early-stage breast cancerOver the last decades, systemic therapy for patients with early-stage breast cancer has undergone remarkable enhancements, with the objectives and structures of neoadjuvant clinical trials continuously developing.
In this podcast, we are joined by Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, as they discuss advances in early-stage HER2-positive, HR-positive and triple-negative breast cancer.
The post Latest advances in...2023-08-2515 minVJOncology PodcastLatest advances in early-stage breast cancerOver the last decades, systemic therapy for patients with early-stage breast cancer has undergone remarkable enhancements, with the objectives and structures of neoadjuvant clinical trials continuously developing. In this podcast, we are joined by Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, as they discuss advances in early-stage HER2-positive, HR-positive and triple-negative breast cancer.
2023-08-2514 min
Oncology Data AdvisorExpert Perspectives in the Management of Triple-Negative Breast Cancer:Webinar Preview, Sara Tolaneyi3 Health is pleased to be hosting Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC): Case Explorations and Answers to FAQs, a live webinar, on July 12, 2023 at 1:00 pm EST, chaired by Dr. Sara Tolaney and Dr. Ira Bleiweiss. In this video interview, Dr. Tolaney shares a preview of the important topics she will be discussing in the webinar, including approaches to treatment selection, the emerging role of novel therapies, timely management of adverse events, and much more. Watch the video to gain insight into the factors Dr. Tolaney takes into account in the management of...2023-07-1013 min
OnconewsAssociação de HER2DX com pCR e sobrevida no câncer de mama HER2+ e prevalência de câncer de mama em cirurgiãs ortopédicasReferências:
Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C,
Echavarría I, López-Tarruella S, Roche-Molina M, del Monte-Millán M,
Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Dieci MV, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa
P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín
M, Prat A, Tolaney SM, Association of HER2DX with pathological complete
response and survival outcomes in HER2-positive...2023-06-2824 min
Research To Practice | Oncology VideosBreast Cancer | Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part SeriesFeaturing perspectives from Dr Sara Tolaney, including the following topics: • Introduction (00:00) • Case: A premenopausal woman in her early 30s with T1c N0 ER/PR-positive, HER2-negative, gBRCA2-mutant invasive ductal carcinoma (IDC) with an Oncotype DX® Recurrence Score® (RS) of 30 receives adjuvant chemotherapy followed by leuprolide/letrozole but wishes to discontinue treatment to attempt pregnancy — Alan B Astrow, MD (10:19) • Case: A woman in her late 30s with T2 N0 ER/PR-positive, HER2-negative IDC and RS of 35 has severe menopause after adjuvant TC, TAH/BSO and letrozole — Ranju Gupta, MD (22:18) • Case: A postmenopausal wom...2023-03-311h 00Breast Cancer UpdateMeet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part SeriesFeaturing a discussion on the management of ER-positive and triple-negative breast cancer with Dr Sara Tolaney, moderated by Dr Neil Love. ?2023-03-311h 00VJOncology PodcastChemotherapy, post-adjuvant therapy, and clinical trial ethics at St Gallen BCC 2023The St Gallen Breast Cancer Congress took place on the 15-18 March 2023. Leading researchers and experts were brought together in Vienna, Austria, to discuss and debate the most important updates in breast cancer. In this podcast, we’ll run through research updates spanning from early treatment to post-adjuvant therapy and a taste of the ethical considerations involved in recruiting for clinical trials. We’ll be hearing from Prof. Philip Poortmans of AZ Sint-Augustinus – Oncologisch Centrum GZA, Dr Lisa Carey of UNC Lineberger Comprehensive Cancer Center, Dr Marleen Kok of the Netherlands Cancer Institute, Dr Hope S. Rugo of Helen Diller...2023-03-3118 minVJOncology PodcastChemotherapy, post-adjuvant therapy, and clinical trial ethics at St Gallen BCC 2023The St Gallen Breast Cancer Congress took place on the 15-18 March 2023. Leading researchers and experts were brought together in Vienna, Austria, to discuss and debate the most important updates in breast cancer. In this podcast, we’ll run through research updates spanning from early treatment to post-adjuvant therapy and a taste of the ethical considerations involved in recruiting for clinical trials. We’ll be hearing from Prof. Philip Poortmans of AZ Sint-Augustinus – Oncologisch Centrum GZA, Dr Lisa Carey of UNC Lineberger Comprehensive Cancer Center, Dr Marleen Kok of the Netherlands Cancer Institute, Dr Hope S. Rugo of Helen Diller...2023-03-3118 minOnconewsCanabinoides no câncer de mama e resultados de longo prazo do estudo APTReferências:
Bimonte S, Palma G, Cascella M, Cuomo A. Phytocannabinoids in Triple Negative
Breast Cancer Treatment: Current Knowledge and Future Insights. Anticancer Res.
2023 Mar;43(3):993-1000. doi: 10.21873/anticanres.16243. PMID: 36854495. https://ar.iiarjournals.org/content/43/3/993
Sara M Tolaney, MD; Paolo Tarantino, MD; Noah Graham, MB; Nabihah Tayob, PhD;
Laia Parè, PhD; Guillermo Villacampa et al. Adjuvant paclitaxel and trastuzumab
for node-negative, HER2-positive breast cancer: final 10-year analysis of the
open-label, single-arm, phase 2 APT trial. Published: March, 2023 DOI: https://doi.org/10.1016/S1470-2045(23)00051-7 ou https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00051-7/fulltext
...2023-03-2223 minVJOncology PodcastBreast Cancer Sessions: Highlights from SABCS 2022 with Sara Tolaney, Paolo Tarantino & Sarah SammonsThe San Antonio Breast Cancer Symposium (SABCS) 2022 took place on the 6-10th of December 2022 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.
In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2022 in an exclusive roundtable discussion. Topics covered include updates on the use of the AKT inhibitor capivasertib, latest SERD data including elacestrant...2023-01-2726 minVJOncology PodcastBreast Cancer Sessions: Highlights from SABCS 2022 with Sara Tolaney, Paolo Tarantino & Sarah SammonsThe San Antonio Breast Cancer Symposium (SABCS) 2022 took place on the 6-10th of December 2022 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.
In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2022 in an exclusive roundtable discussion. Topics covered include updates on the use of the AKT inhibitor capivasertib, latest SERD data including elacestrant...2023-01-2526 min
CCO Oncology PodcastIndividualizing Care for Patients With Triple-Negative Breast CancerIn this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBCRole of PARP...2023-01-1836 min
Research To Practice | Oncology VideosHER2-Positive Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast CancerFeaturing perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31) Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05) Dr Tolaney presentation (18:44) Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 60s with an 8-cm, ER-ne...2022-12-222h 10
Oncology Brothers: Practice-Changing Cancer DiscussionsCDK4/6i in HR+ SABCS 2022 Highlights with Dr. Sara TolaneyDiscussing Hormone Receptor Positive (HR+) Highlights from SABCS 2022 on usage of CDK4/6 inhibitors - Practice changing studies with Dr. Sara Tolaney, Chief - Division of Breast Oncology at Dana-Farber and Associate Professor at Harvard Medical School.
CME information and credit available at: https://integrityce.com/courses/clinical-updates-from-san-antonio-hr-her2-breast-cancer-cdk-4-6-inhibitors/
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
2022-12-1414 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast CancerGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on...2022-10-2155 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast CancerGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on...2022-10-2155 minPeerView Clinical Pharmacology CME/CNE/CPE VideoSara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast CancerGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on...2022-10-2155 minPeerView Internal Medicine CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast CancerGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on...2022-10-2155 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast CancerGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on...2022-10-2155 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast CancerGo online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on...2022-10-2155 min
Oncology On The GoOncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCOIn the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs c...2022-06-3044 min
Research To Practice | Oncology VideosBreast Cancer| Proceedings from a CME Hybrid Symposium Series Held in Conjunction with the 2022 ASCO Annual MeetingFeaturing perspectives from Drs Javier Cortés, Matthew Goetz, Erika Hamilton, Ian Krop, Hope Rugo and Sara Tolaney, including the following topics: Introduction (0:00) Optimizing the Management of ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (7:50) New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC) — Erika Hamilton, MD (38:35) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (56:03) Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Javier Cortés, MD, PhD (1:18:47) Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC — Hope S Rugo, MD (1:40:41) Recent Advances in the...2022-06-282h 30
OnconewsctDNA, recorrência tardia e impacto dos estudos RxPONDER e monarchE no manejo cirúrgico da axilaOs resultados dos ensaios RxPONDER e monarchE informaram as recomendações de terapia sistêmica para câncer de mama RH+, HER2-negativo. Dada a importância da extensão da doença nodal nesses estudos, o manejo cirúrgico da axila ressurgiu como uma questão importante. Esses pacientes precisariam de uma maior dissecção de linfonodos axilares (ALND) para determinar a carga nodal total e informar as recomendações de terapia sistêmica? O assunto foi tema de artigo de opinião no Journal of Global Oncology (JCO) e está em pauta em mais um PODCAST ONCONEWS. Nessa edição, Si...2022-06-2421 minPeerView Clinical Pharmacology CME/CNE/CPE VideoSara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor TherapyGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recu...2022-02-0429 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor TherapyGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recu...2022-02-0429 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor TherapyGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recu...2022-02-0429 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor TherapyGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recu...2022-02-0429 minPeerView Internal Medicine CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor TherapyGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recu...2022-02-0429 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastSara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor TherapyGo online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recu...2022-02-0429 min
Breastcancer.org PodcastTop Research Presented at the 2021 San Antonio Breast Cancer SymposiumDr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical School.The 2021 San Antonio Breast Cancer Symposium featured four days of presentations on the latest research on breast cancer. Dr. Tolaney joined us to discuss the research that is most immediately applicable to people who’ve been diagnosed with the disease.Listen to the episode to hear Dr. Tolaney explain:
results of an early study look...2021-12-2110 min
Oncology Data AdvisorImproving the Management of Metastatic Breast Cancer: A Conversation With Dr. Sara TolaneyIn this podcast, Dr. Sara Tolaney from Dana-Farber Cancer Institute will be discussing strategies to improve the management of metastatic breast cancer.
If you enjoyed this podcast and want to learn more on Optimizing Personalized Care Plans for Patients With Metastatic Breast Cancer, visit i3Health.com/metastatic-bc for free CME/NCPD.2021-09-0709 minVJOncology PodcastThe Breast Cancer Sessions: Highlights from ASCO 2021VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.
Tune in to hear the expert...2021-08-1839 minVJOncology PodcastThe Breast Cancer Sessions: Highlights from ASCO 2021VJOncology has assembled an international panel of leading breast cancer experts to discuss the latest advances and data from the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
In this podcast, Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Giuseppe Curigliano, MD, University of Milan, Milan, Italy, Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, and Andrew Tutt, MBChB, PhD, The Institute of Cancer Research, London, UK, to examine the recent major breakthroughs in breast cancer and what they mean for clinical practice.
Tune in to hear the expert...2021-08-1639 min
CCO Oncology PodcastCDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician QuestionsIn this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifenPresenters:Javier Cortes, MD, PhDHead, Breast Cancer ProgramIOB Institute of OncologyMadrid and Barcelona, SpainStephen R. D. Johnston, MA, FRCP, PhDProfessor of Breast Cancer Medicine2021-08-0508 minVJOncology PodcastKey trial updates at SABCS 2020: monarchE, RxPONDER & ASCENTThe San Antonio Breast Cancer Symposium (SABCS) 2020 annual meeting took place virtually this year and showcased recent advances in the treatment and management of breast cancer.
In this podcast, Priya Rastogi, MD, of the University of Pittsburgh, Pittsburgh, PA, Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute, Boston, MA, and Sara Hurvitz, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, outline key trial updates presented at SABCS 2020, including the primary outcome results of the monarchE study (NCT02107703), the practice-changing findings of RxPONDER (NCT01272037), and the updated biomarker analysis of the ASCENT study (NCT02574455...2020-12-1510 min
Journal of Clinical Oncology (JCO) PodcastExpanding Treatment Options for Hormone Receptor-Positive, HER2-Positive Metastatic Breast CancerRead the related article "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial" by Rimawi et al on JCO.org. Transcript: This JCO Podcast provides observations and commentary on the JCO article ‘First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial’ by Rimawi et al. My name is Sara Tolan...2018-08-1408 min
Journal of Clinical Oncology (JCO) PodcastExpanding Treatment Options for Hormone Receptor-Positive, HER2-Positive Metastatic Breast CancerRead the related article "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial" by Rimawi et al on JCO.org. Transcript: This JCO Podcast provides observations and commentary on the JCO article ‘First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial’ by Rimawi et al. My name is Sara Tolan...2018-08-1408 min